• If you are wondering whether CME Group's current share price gives you fair value or a margin of safety, it helps to break the stock down into what you are really paying for.
• The stock recently closed at US$291.23, with returns of 8.0% year to date, 6.4% over 1 year, 64.1% over 5 years, and 87.6% over 3 years. Over the last 7 days the price declined 2.6%, and over the last 30 days it showed a gain of 1.9%.
• Recent coverage around CME Group has focused on its role as a major financial market infrastructure provider and how investors use the stock as a way to gain exposure to trading and hedging activity across asset classes. This context helps explain why the market can quickly rethink the stock's risk and return profile when expectations for activity in futures and options markets shift.
• Simply Wall St currently assigns CME Group a valuation score of 2 out of 6, reflecting that the stock screens as undervalued on only some checks. The rest of this article will compare several common valuation approaches and, at the end, introduce a way of assessing value that goes beyond a single metric.

CME Group scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: CME Group Excess Returns Analysis

The Excess Returns model looks at how much value a company can create over and above the return that equity investors require. Instead of focusing on cash flows, it starts from the balance sheet and earnings power, then estimates how much “extra” return CME Group can generate on its equity base.

For CME Group, the model uses a Book Value of $73.57 per share and a Stable EPS of $13.63 per share, based on weighted future Return on Equity estimates from 5 analysts. The Average Return on Equity is 15.97%, while the implied Cost of Equity is $6.67 per share. That gap produces an Excess Return of $6.96 per share. The Stable Book Value used in the model is $85.34 per share, sourced from weighted future Book Value estimates from 3 analysts.

Combining these inputs, the Excess Returns model arrives at an intrinsic value of about $248.05 per share. Compared with the recent share price of $291.23, this framework suggests CME Group is around 17.4% overvalued on this metric.

Result: OVERVALUED

Our Excess Returns analysis suggests CME Group may be overvalued by 17.4%. Discover 52 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: CME Group Price vs Earnings

P/E is a common way to value profitable companies because it directly links what you pay for each share to the earnings that share generates. In simple terms, a higher P/E usually reflects higher growth expectations or a lower perceived risk, while a lower P/E can signal lower growth expectations or higher perceived risk.

CME Group currently trades on a P/E of 24.9x. This sits below the wider Capital Markets industry average of 39.9x, and also below the 26.6x average of its peer group. On the surface that might suggest the stock is priced more conservatively than many competitors.

Simply Wall St also calculates a “Fair Ratio”, which is the P/E that would typically be expected for CME Group given factors such as its earnings profile, industry, profit margins, market cap and risk characteristics. For CME Group, this Fair Ratio is 15.5x. Because it looks at company specific drivers rather than just broad peer or industry averages, the Fair Ratio can give a more tailored sense of what an appropriate multiple might be.

Comparing the current P/E of 24.9x with the Fair Ratio of 15.5x suggests the stock is trading above this proprietary benchmark.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your CME Group Narrative

Earlier it was mentioned that there is an even better way to understand valuation. It helps to think in terms of Narratives, which are simple stories you create about CME Group that link your view of its business to explicit forecasts for revenue, earnings and margins, and then to your own fair value estimate.

On Simply Wall St, Narratives on the Community page let you set those assumptions in a structured way, compare the fair value that drops out of your story with the current share price, and quickly see whether the gap suggests the stock might be expensive or cheap on your numbers.

Because Narratives are tied to live data, they update when new information such as earnings, product launches or fresh analyst views is added. This means you do not have to rebuild your work every time the situation changes.

For CME Group, one investor might lean toward the higher analyst price target of US$353.0 if they focus on growth in areas like retail engagement and new contracts. Another might anchor closer to the lower US$230.0 target if they are more concerned about competition, regulation and volume risk. Narratives give you a clear, side by side way to see how those different stories translate into different fair values.

Do you think there's more to the story for CME Group? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.